ByTrending Posts
Roche Doubles Down on U.S. Biomanufacturing: $2 Billion…
23 January 2026 Executive Summary Roche’s Genentech unit announced a major expansion of its biomanufacturing facility in Holly…
Can Johnson & Johnson’s $550 Million Vision Care…
23 January 2026 Executive Summary Johnson & Johnson’s Vision Care division is advancing a major U.S. expansion project,…
Can Johnson & Johnson Hit $100 Billion in…
23 January 2026 Executive Summary Johnson & Johnson (J&J) has issued a bullish 2026 revenue forecast, projecting nearly…
Can AI-Driven Chemistry Partnerships Like Merck–ChemLex Accelerate Drug…
23 January 2026 Executive Summary Merck has signed a Memorandum of Understanding (MoU) with ChemLex, initiating a strategic…
FDA Grants Breakthrough Therapy Status to Lilly’s Folate…
23 January 2026 Executive Summary Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has granted…
Despite Geopolitical Tensions, U.S.–China Biotech Interdependence Remains Central
23 January 2026 Executive Summary Industry reports continue to underscore the deep interdependence between U.S. and Chinese biotech…
Are China’s Innovation and Cost Advantages Redrawing Global…
23 January 2026 Executive Summary Competitive dynamics across global biopharma in 2026 are being fundamentally reshaped by China’s…
Is China Outpacing the Global Biopharma Cycle? Innovation…
23 January 2026 Executive Summary China’s biopharma sector is continuing to advance at remarkable speed, with recent analyses…
Is China Becoming a Power Center for AI-Led…
23 January 2026 Executive Summary Artificial-intelligence-driven drug developer Insilico Medicine has entered into a $66 million licensing agreement…
Trending Posts
Latest Stories
Can Novo Nordisk Defend Its Obesity Crown as Competition With Eli Lilly Intensifies in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Obesity & Metabolic Disease Strategy Novo…
Will Eli Lilly’s 2025 Earnings Prove That AI Is the Hidden Engine Behind Its Next Phase of Scale?
Late January 2026 | Full-Year 2025 Earnings Preview | AI-Driven Biopharma Leadership Eli Lilly is…
Will Sanofi’s 2025 Earnings Cement Dupixent’s Leadership—and Its Next Growth Wave in Atopic Dermatitis?
Late January 2026 | Full-Year 2025 Earnings Preview | Immunology & Dermatology Focus Sanofi is…
Can AbbVie’s 2025 Earnings Prove Its Post-Humira Portfolio Is Built for the Next Decade?
Late January 2026 | Full-Year 2025 Earnings Preview | Biopharma Growth Strategy AbbVie is set…
Gallery
